RoosterBio & Secretome Therapeutics Announce Successful Completion of Large Scale Production for Clinical Stage Cell Therapy Candidate

Portfolio company RoosterBio, in partnership with Secretome Therapeutics, announced the successful completion of large-scale bioreactor production for Secretome’s clinical-stage cell therapy candidate, STM-01. The milestone marks a key step toward commercial manufacturing readiness and demonstrates the scalability of RoosterBio’s bioprocessing platform.

Why it matters:

• De-risking scale-up: Transition from 2D flask to 50 L bioreactor manufacturing validates RoosterBio’s cGMP system for late-stage production.

• Accelerated path to clinic: Streamlined, reproducible bioprocess supports faster advancement of Secretome’s pipeline into pivotal trials.

• Platform leverage: Reinforces RoosterBio’s position as an enabling technology provider for the growing field of cell and secretome-based therapeutics.